Search

Your search keyword '"Abdelrahim Maen"' showing total 10 results
Start Over Author "Abdelrahim Maen" Journal molecular cancer therapeutics
10 results on '"Abdelrahim Maen"'

1. Abstract B82: Olanzapine for cachexia in patients with advanced cancer.

Author

Abdelrahim, Maen, primary, Naing, Aung, additional, Dalal, Shalini, additional, Wheler, Jennifer, additional, Hess, Kenneth, additional, Fu, Siqing, additional, Hong, David S., additional, Janku, Filip, additional, Falchook, Gerald S., additional, Ilustre, Alyson, additional, Ouyang, Fengying, additional, and Kurzrock, Razelle, additional

Published
2013
Full Text
View/download PDF

2. Abstract C69: Phase I trial of lenalidomide and valproic acid in patients with advanced cancer.

Author

Bilen, Mehmet A., primary, Fu, Siqing, additional, Hong, David S., additional, Wheler, Jennifer J., additional, Abdelrahim, Maen, additional, Falchook, Gerald S., additional, Tsimberidou, Apostlia M., additional, Janku, Filip, additional, Piha-Paul, Sarina, additional, Zinner, Ralph, additional, Kurzrock, Razelle, additional, and Naing, Aung, additional

Published
2013
Full Text
View/download PDF

8. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells

Author

Konopleva, Marina, primary, Zhang, Weiguo, additional, Shi, Yue-Xi, additional, McQueen, Teresa, additional, Tsao, Twee, additional, Abdelrahim, Maen, additional, Munsell, Mark F., additional, Johansen, Mary, additional, Yu, Dihua, additional, Madden, Timothy, additional, Safe, Stephen H., additional, Hung, Mien-Chie, additional, and Andreeff, Michael, additional

Published
2006
Full Text
View/download PDF

9. A new class of peroxisome proliferator-activated receptor γ (PPARγ) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes

Author

Qin, Chunhua, primary, Morrow, Derek, additional, Stewart, Jessica, additional, Spencer, Kyle, additional, Porter, Weston, additional, Smith, Roger, additional, Phillips, Timothy, additional, Abdelrahim, Maen, additional, Samudio, Ismael, additional, and Safe, Stephen, additional

Published
2004
Full Text
View/download PDF

10. A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes.

Author

Qin C, Morrow D, Stewart J, Spencer K, Porter W, Smith R 3rd, Phillips T, Abdelrahim M, Samudio I, and Safe S

Subjects
3T3-L1 Cells, Adipocytes cytology, Animals, Apoptosis, Carcinogens, Cell Cycle, Cell Differentiation, Cell Division, Cell Line, Tumor, Cell Separation, Cloning, Molecular, Cyclin D1 biosynthesis, Dose-Response Relationship, Drug, Down-Regulation, Estrogen Receptor alpha, Female, Flow Cytometry, G1 Phase, Humans, Indoles chemistry, Ligands, Luciferases metabolism, Mice, Plasmids metabolism, Prostaglandin D2 pharmacology, Protein Structure, Tertiary, Rats, Rats, Sprague-Dawley, Receptors, Cytoplasmic and Nuclear metabolism, Receptors, Estrogen metabolism, Resting Phase, Cell Cycle, Structure-Activity Relationship, Transcription Factors metabolism, Transcriptional Activation, Transfection, Two-Hybrid System Techniques, Breast Neoplasms drug therapy, Indoles pharmacology, Methane pharmacology, Prostaglandin D2 analogs & derivatives, Receptors, Cytoplasmic and Nuclear agonists, Transcription Factors agonists
Abstract

1,1-Bis(3'-indolyl)-1-(p-trifluoromethylphenyl)methane (DIM-C-pPhCF(3)) and several p-substituted phenyl analogues have been investigated as a new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. Structure-activity studies in PPARgamma-dependent transactivation assays in MCF-7 breast cancer cells show that 5-20 micro M concentrations of compounds containing p-trifluoromethyl, t-butyl, cyano, dimethylamino, and phenyl groups were active, whereas p-methyl, hydrogen, methoxy, hydroxyl, or halogen groups were inactive as PPARgamma agonists. Induction of PPARgamma-dependent transactivation by 15-deoxy-Delta12,14-prostaglandin J2 (PGJ2) and DIM-C-pPhCF(3) was inhibited in MCF-7 cells cotreated with the PPARgamma-specific antagonist N-(4'-aminopyridyl)-2-chloro-5-nitrobenzamide. In mammalian two-hybrid assays, DIM-C-pPhCF(3) and PGJ2 (5-20 micro M) induced interactions of PPARgamma with steroid receptor coactivator (SRC) 1, SRC2 (TIFII), and thyroid hormone receptor-associated protein 220 but not with SRC3 (AIB1). In contrast, DIM-C-pPhCF(3), but not PGJ2, induced interactions of PPARgamma with PPARgamma coactivator-1. C-substituted diindolylmethanes inhibit carcinogen-induced rat mammary tumor growth, induce differentiation in 3T3-L1 preadipocytes, inhibit MCF-7 cell growth and G(0)/G(1)-S phase progression, induce apoptosis, and down-regulate cyclin D1 protein and estrogen receptor alpha in breast cancer cells. These compounds are a novel class of synthetic PPARgamma agonists that induce responses in MCF-7 cells similar to those observed for PGJ2.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results